Australia markets open in 8 hours 32 minutes
  • ALL ORDS

    7,552.10
    -40.60 (-0.53%)
     
  • AUD/USD

    0.7589
    +0.0035 (+0.46%)
     
  • ASX 200

    7,298.50
    -43.70 (-0.60%)
     
  • OIL

    73.65
    +0.80 (+1.10%)
     
  • GOLD

    1,788.60
    +11.20 (+0.63%)
     
  • BTC-AUD

    44,226.58
    +2,659.48 (+6.40%)
     
  • CMC Crypto 200

    809.31
    -0.88 (-0.11%)
     

Scott+Scott Attorneys at Law LLP Announces Investigation into Frequency Therapeutics, Inc. (FREQ)

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
  • Oops!
    Something went wrong.
    Please try again later.

Scott+Scott Attorneys at Law LLP ("Scott+Scott"), an international shareholder and consumer rights litigation firm, is investigating whether Frequency Therapeutics, Inc. ("Frequency" or the "Company") (NASDAQ: FREQ), or certain of its officers and directors, violated federal securities laws. If you purchased Frequency common stock and recently suffered a loss, you are encouraged to contact Scott+Scott attorney Joe Pettigrew at 844-818-6982 or jpettigrew@scott-scott.com for more information.

Frequency is a clinical-stage biotechnology company. Its lead product candidate is FX-322, a potential treatment for hearing loss.

Our investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Frequency issued a press release on March 23, 2021, announcing topline data from its FX-322 Phase 2a study (FX-322-202). The Company admitted that "the interim results show that four weekly injections in subjects with mild to moderately severe sensorineural hearing loss (SNHL) did not demonstrate improvements in hearing measures versus placebo."

On this news, Frequency’s stock price fell $28.30 per share – nearly 78% – to close at $7.99 per share on March 23, 2021.

What You Can Do

If you purchased Frequency common stock, and you wish to discuss this investigation, please contact attorney Joe Pettigrew at 844-818-6982, or at jpettigrew@scott-scott.com, or visit the Frequency investigation page on our website at https://scott-scott.com/investigation/frequency-therapeutics-inc/.

About Scott+Scott Attorneys at Law LLP

Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Amsterdam, Connecticut, California, Virginia, and Ohio.

Attorney Advertising

View source version on businesswire.com: https://www.businesswire.com/news/home/20210518006061/en/

Contacts

Joe Pettigrew
Scott+Scott Attorneys at Law LLP
230 Park Avenue, 17th Floor, New York, NY 10169
844-818-6982
jpettigrew@scott-scott.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting